Expression of vascular endothelial growth factor and its receptors KDR and Flt1 in acute myeloid leukemia.
- Author:
Yi WANG
1
;
Zhi-jian XIAO
;
Peng LIU
;
Chen YANG
;
Ren-chi YANG
;
Ying-lin CAI
;
Zhong-chao HAN
Author Information
- Publication Type:Journal Article
- MeSH: Enzyme-Linked Immunosorbent Assay; Humans; Leukemia, Myeloid, Acute; drug therapy; metabolism; RNA, Messenger; genetics; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; biosynthesis; genetics; Vascular Endothelial Growth Factor Receptor-1; biosynthesis; genetics; Vascular Endothelial Growth Factor Receptor-2; biosynthesis; genetics
- From: Chinese Journal of Hematology 2003;24(5):249-252
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the expression of vascular endothelial growth factor (VEGF) and its receptors KDR and Flt1 in patients with acute myeloid leukemia (AML).
METHODSThe expression of VEGF and its receptors mRNA was assayed by RT-PCR, the plasma of VEGF by ELISA.
RESULTSIn 13 AML cell lines, the expression of VEGF, KDR and Flt1 mRNA were found in 13 (100%), 7 (53.8%) and 12 (92.3%), respectively. There were 21 (65.6%), 1 (3.1%), and 17 (53.1%) of 31 (AML) patients bone marrow mononuclear cells (BMMNCs) expressing VEGF, KDR and Flt1 mRNA, respectively. None of BMMNCs from 3 normal donor and CD(34)(+) cells from 2 normal donor was found to express VEGF, KDR and Flt1 mRNA. The plasma level of VEGF of 39 patients (new diagnosed, relapsed and secondary-AML) before treatment was (135.3 +/- 87.9) ng/L which was significantly higher than that of 15 complete remission (CR) patients (80.6 +/- 36.9) ng/L and 12 normal donors (80.6 +/- 33.1) micro g/L (P = 0.028, 0.007). The plasma level of VEGF of 15 non-responsive patients was (188.2 +/- 118.6) ng/L after two cycles of chemotherapy which was higher than that of 20 CR patients [(104.2 +/- 30.9) ng/L] (P = 0.004).
CONCLUSIONVEGF and its receptors KDR and Flt1 mRNAs were expressed in BMMNCs of AML patients. The plasma level of VEGF directly affected the response to chemotherapy in AML patients.
